Trichostatin A (TSA) inhibits all histone deacetylases (HDACs) of both class I and II, whereas trapoxin (TPX) cannot inhibit HDAC6, a cytoplasmic member of class II HDACs. We took advantage of this differential sensitivity of HDAC6 to TSA and TPX to identify its substrates. Using this approach, a-tubulin was identi®ed as an HDAC6 substrate. HDAC6 deacetylated a-tubulin both in vivo and in vitro. Our investigations suggest that HDAC6 controls the stability of a dynamic pool of microtubules. Indeed, we found that highly acetylated microtubules observed after TSA treatment exhibited delayed drug-induced depolymerization and that HDAC6 overexpression prompted their induced depolymerization. Depolymerized tubulin was rapidly deacetylated in vivo, whereas tubulin acetylation occurred only after polymerization. We therefore suggest that acetylation and deacetylation are coupled to the microtubule turnover and that HDAC6 plays a key regulatory role in the stability of the dynamic microtubules.

By methylation of peptide arrays, we determined the specificity profile of the protein methyltransferase G9a. We show that it mostly recognizes an Arg-Lys sequence and that its activity is inhibited by methylation of the arginine residue. Using the specificity profile, we identified new non-histone protein targets of G9a, including CDYL1, WIZ, ACINUS and G9a (automethylation), as well as peptides derived from CSB. We demonstrate potential downstream signaling pathways for methylation of non-histone proteins.Epigenetic regulation of gene expression by covalent modification of histone proteins and methylation of DNA controls development and disease processes 1 . Post-translational modification of histone proteins includes acetylation, phosphorylation and methylation. Many of these modifications occur on the N-terminal tails of the histone proteins that protrude from the nucleosome. Methylation of lysine residues in histone tails has been identified in histone H3 lysine residues 4, 9, 27 and 36; in histone H4 lysine 20; and in histone H1b lysine 25. Each of these methylations has different biological functions 1 .The first histone lysine methyltransferase was identified in 2000 (ref.2), and today about 30 different enzymes are known in different species 1 . Most protein lysine methyltransferases (PKMTs) contain a SET domain, which harbors the active center of the enzymes 3 . Here, we investigate the substrate sequence specificity of the human G9a PKMT, which is important for the euchromatic histone H3K9 methylation that is essential for early embryogenesis 4 , the propagation of imprints 5 and control of DNA methylation 6 . Knockout of G9a results in a decrease of global H3K9me1 and H3K9me2 levels 7 . In vitro G9a generates mainly H3K9me1 and H3K9me2 (ref. 8), as well as H3K9me3 after long incubation 9 . In contrast to the Dim-5 and Suv39H1 H3K9 methyltransferases, G9a methylates not only H3K9 but also H3K27 (ref. 10), which implicates different specificities in peptide recognition. To analyze the substrate specificity of PKMTs, we prepared peptide arrays on functionalized cellulose membranes using the first 21 residues of histone H3 as template 11 (Supplementary Methods online). The membranes were incubated with G9a in the presence of radioactively labeled [methyl-3 H]-S-adenosyl-L-methionine ( 3 H-AdoMet, 1), and the transfer of methyl groups to the immobilized peptides was detected by autoradiography ( Supplementary Fig. 1 online). To quantify the contribution of each amino acid to the recognition of the substrate and display it graphically, the discrimination factor of G9a at each position was calculated (Fig. 1a). The results showed that G9a interacts with H3 residues 6-11, which agrees with a report describing a heptapeptide of the histone H3 tail (TARKSTG) as the minimal substrate methylated by G9a (ref. 12). In addition to Lys9 (the target of methylation), Arg8 is the most important specificity determinant for G9a. Any other amino acid substituted at that position completely abolished the activity...

Trichostatin A (TSA) and trapoxin (TPX), inhibitors of the eukaryotic cell cycle and inducers of morphological reversion of transformed cells, inhibit histone deacetylase (HDAC) at nanomolar concentrations. Recently, FK228 (also known as FR901228 and depsipeptide) and MS-275. antitumor agents structurally unrelated to TSA, have been shown to be potent HDAC inhibitors. These inhibitors activate the expression of p21Waf1 in a p53-independent manner. Changes in the expression of regulators of the cell cycle, differentiation, and apoptosis with increased histone acetylation may be responsible for the cell cycle arrest and antitumor activity of HDAC inhibitors. TSA has been suggested to block the catalytic reaction by chelating a zinc ion in the active site pocket through its hydroxamic acid group. On the other hand, an epoxyketone has been suggested to be the functional group of TPX capable of alkylating the enzyme. We synthesized a novel TPX analogue containing a hydroxamic acid instead of the epoxyketone. The hybrid compound, called cyclic hydroxamic-acid-containing peptide 1 (CHAP1) inhibited HDAC at low nanomolar concentrations. The HDAC1 inhibition by CHAPI was reversible, as is that by TSA, in contrast to irreversible inhibition by TPX. Interestingly, HDAC6, but not HDAC1 or HDAC4, was resistant to TPX and CHAP1, while TSA inhibited these HDACs to a similar degree. CHAP31, the strongest HDAC inhibitor obtained from a variety of CHAP derivatives, exhibited antitumor activity in BDF1 mice bearing B16/BL6 tumor cells. These results suggest that CHAP31 is promising as a novel therapeutic agent for cancer treatment, and that CHAP may serve as a basis for new HDAC inhibitors and be useful for combinatorial synthesis and high-throughput screening.

Trichostatin A (TSA) and trapoxin (TPX) are potent inhibitors of histone deacetylases (HDACs). TSA is proposed to block the catalytic reaction by chelating a zinc ion in the active-site pocket through its hydroxamic acid group. On the other hand, the epoxyketone is suggested to be the functional group of TPX capable of alkylating the enzyme. We synthesized a novel TPX analogue containing a hydroxamic acid instead of the epoxyketone. The hybrid compound cyclic hydroxamic acid-containing peptide (CHAP) 1 inhibited HDAC1 at low nanomolar concentrations. The HDAC1 inhibition by CHAP1 was reversible as it was by TSA, in contrast to the irreversible inhibition by TPX. CHAP with an aliphatic chain length of five, which corresponded to that of acetylated lysine, was stronger than those with other lengths. These results suggest that TPX is a substrate mimic and that the replacement of the epoxyketone with the hydroxamic acid converted TPX to an inhibitor chelating the zinc like TSA. Interestingly, HDAC6, but not HDAC1 or HDAC4, was resistant to TPX and CHAP1, whereas TSA inhibited these HDACs to a similar extent. HDAC6 inhibition by TPX at a high concentration was reversible, probably because HDAC6 is not alkylated by TPX. We further synthesized the counterparts of all known naturally occurring cyclic tetrapeptides containing the epoxyketone. HDAC1 was highly sensitive to all these CHAPs much more than HDAC6, indicating that the structure of the cyclic tetrapeptide framework affects the target enzyme specificity. These results suggest that CHAP is a unique lead to develop isoform-specific HDAC inhibitors.